Frederick, Maryland (PRWEB)
May 04, 2017
At a CAGR of 23.2% and estimated revenue of $68B by 2020, the Regenerative Medicine (“RM”) industry continues to call for new tools designed to accelerate this aggressive growth. Based on strong RM market demand, RoosterBio Inc today announces the launch of xeno-free (“XF”) human bone-marrow derived mesenchymal stem/stromal cell (hMSC) products.
The RoosterVial™-XF line of products are cryopreserved human bone marrow-derived MSCs, designed to serve as manufacturing starting materials, and are offered in various high volume formats, including 1, 10 and 50 million cells per vial. These first-in-class xeno-free hMSC cell bank product offerings expand RoosterBio’s development grade product portfolio and are complementary to RoosterBio’s other industry-leading stem cell bioprocessing systems.
First generation cell therapies traditionally relied on bovine serum in their manufacturing processes. As the industry evolves, the market is seeking more sophisticated XF tools and processes. RoosterBio is bringing these XF design requirements into its biomanufacturing product configurations with the goal of reducing regulatory burden and enhancing the long-term safety profile of cell-based therapies. By incorporating XF starting materials at early stages of product development, RM scientists can perform more clinically relevant work, resulting in an expedited path towards clinical testing programs.
Jon A Rowley, RoosterBio’s Chief Technology Officer, states, “We’re very excited to launch this product line, particularly as it relates to advancing the RM industry. Last year, we launched XF bioprocess media, and now we’re introducing the XF cell banks to complete the system. Together, these products give our customers all the tools they need…